申请人:Sterling Drug Inc.
公开号:US04363911A1
公开(公告)日:1982-12-14
1-R.sub.1 -1,2-dihydro-6-[2-(dimethylamino)ethenyl]-2-oxo-5-PY-nicotinonitriles, where R.sub.1 is hydrogen or methyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically acceptable acid-addition salts thereof are useful as cardiotonic agents. Said compounds are prepared by reacting 1,2-dihydro-6-methyl-2-oxo-5-PY-nicotinonitrile with dimethylformamide dimethylacetal. Shown is the cardiotonic use of said compounds or pharmaceutically acceptable acid-addition salts thereof.
R.sub.1 -1,2-二氢-6-[2-(二甲基氨基)乙烯基]-2-氧代-5-PY-烟酰腈,其中R.sub.1是氢或甲基,PY是4-或3-吡啶基或带有一个或两个较低烷基取代基的4-或3-吡啶基,或其药学上可接受的酸盐,可用作心力衰竭药物。这些化合物是通过将1,2-二氢-6-甲基-2-氧代-5-PY-烟酰腈与二甲基甲醛缩二甲醚反应制备的。所述化合物或其药学上可接受的酸盐的心力衰竭用途如图所示。